Coronado Biosciences, Inc. (Nasdaq: CNDO) is a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The Company announced that Lucy Lu, M.D. has joined the Company as Executive Vice President and Chief Financial Officer. Mr. Dale Ritter, current acting Chief Financial Officer, will continue his role as Senior Vice President of Finance and Chief Accounting Officer.
Dr. Bobby W. Sandage, Jr., Coronado's President and CEO, stated:
"We are excited to have Lucy join the Coronado management team. With more than 10 years experience as a Wall Street biotechnology analyst and investment banker, Lucy has a strong financial background and a comprehensive understanding of the drug development process. This valuable knowledge and expertise will be crucial to our organization as we move our TSO and CNDO-109 programs through clinical development to commercialization."
Most recently, Dr. Lu was a Senior Biotechnology Analyst at Citigroup Investment Research where she was responsible for the coverage of small and middle capitalization stocks and the vetting of both public and private companies. Prior to Citigroup, Dr. Lu worked in equity research at First Albany Capital as a Vice President and Principal. She started her career at Lehman Brothers as an Associate of Healthcare Investment Banking.
"I believe that Coronado's pipeline candidates have the potential to be transformative treatments for patients with certain autoimmune conditions and cancer, and I am thrilled to be part of this team," stated Dr. Lu.
Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.